Federal Register
Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; Availability- Facts included
- The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled "Early-Phase IND Protocol Recommendations for Solid Tumors."
- The draft guidance provides recommendations to sponsors and clinical investigators developing early‑phase trials, including first‑in‑human (FIH) protocols or protocols for drugs and biologic products with limited human experience.
- The guidance applies to protocols submitted under an Investigational New Drug Application (IND) to the disease‑specific division within the Office of Oncologic Diseases (OOD) in CDER and the Office of Clinical Evaluation (OCE) in CBER.
- The draft guidance is specific to solid tumors and does not address protocols for investigational drugs intended to treat hematologic malignancies.
- Sourcing
- High – the information comes directly from an FDA announcement, which is a primary, authoritative source.
- Framing
- The text is purely factual reporting of an FDA announcement; it contains no opinion or editorial commentary.
- Omissions
- The announcement does not explain how the draft guidance will affect ongoing or future trial designs, the timeline for public comment, or any potential regulatory implications for sponsors.
- Rhetorical notes (2)
- Official announcement · Scope clarification